PNPLA5

Across TCGA pan-cancer cohorts, PNPLA5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PNPLA5 data layer compared with 15 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PNPLA5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PNPLA5 expression acts as an unfavorable survival marker.

STAD, COAD, and LIHC are the cancer types where PNPLA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.002	18	view →
COAD	DFS	Median	II,III,IV	0.035	0.776	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.178	0.715	.007	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	OS	Median	All	0.176	0.724	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.167	0.653	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PNPLA5–STAD (OS)

Open the STAD breakdown →